Home > Specialists > Nuclear Medicine > Dr. Lei Kang (康磊)
Specialty & Clinical Focus:
Nuclear medicine physician at Peking University First Hospital in Beijing, with a clinical focus on PET/SPECT imaging, I-131 therapy for thyroid conditions, Sr-89 and Ra-223 therapy for bone metastases, and tumor-targeted molecular imaging.
Professional Title & Qualifications:
Chief Physician,
Professor,
Doctoral Supervisor
Hospital & Department：
Peking University First Hospital – Department of Nuclear Medicine
(address: No. 8 Xishiku Street, Xicheng District, Beijing, 100034)
Dr. Lei Kang (康磊) - Nuclear Medicine Physician
Personal Biography
Dr. Lei Kang is Chief Physician, Professor, Doctoral Supervisor, and Director of the Department of Nuclear Medicine at Peking University First Hospital in Beijing. His clinical work includes PET and SPECT examinations, clinical report writing and review, radioactive iodine therapy, and targeted nuclear medicine therapies.
Alongside clinical practice, Dr. Kang focuses on molecular imaging research, including tumor-targeted tracing and in-vivo evaluation techniques. He has independently designed a series of tumor-targeted radioactive molecular probes with independent intellectual property rights.
He is recognized as a Beijing Outstanding Young Scientist and Beijing Science and Technology Nova, and his international training includes fellowship experience at the University of Wisconsin-Madison and the UCLA Ronald Reagan Medical Center PET Center.
Why Choose Dr. Lei Kang?
For international patients considering nuclear medicine options in China, Dr. Lei Kang’s background is especially relevant when cases depend on detailed imaging, pathology, treatment history and precise questions for specialist review. His clinical focus includes I-131 therapy for thyroid conditions, Sr-89 and Ra-223 therapy for bone metastases, PET/SPECT reporting and advanced molecular imaging.
Dr. Kang has managed cases for over 1,700 patients and completed fellowship training at the University of Wisconsin-Madison and the UCLA Ronald Reagan Medical Center PET Center. With nearly 100 SCI publications, his clinical and research background supports focused review of complex nuclear medicine and molecular imaging questions before patients consider further in-person care in Beijing.
Pre-Travel Case Review & Specialist Liaison
International travel for nuclear medicine care requires careful preparation, especially when PET/SPECT imaging, thyroid disease treatment history, bone metastasis treatment records or prior oncology reports need to be reviewed. Before pursuing an in-person pathway in Beijing, international patients can request MedBridgeNZ coordination for a remote specialist-review pathway with Dr. Lei Kang’s office where available.
With the patient’s authorization, MedBridgeNZ helps organize medical records, imaging files, translation coordination, secure document transfer and appointment request communication. The relevant third-party specialist office will review submitted records for appointment triage or preliminary case-screening where available, helping patients better understand administrative readiness and travel feasibility before the next step.
Disclaimer: MedBridgeNZ is a medical concierge provider serving a global client base. We assist with logistical coordination and facilitate access to healthcare professionals. MedBridgeNZ does not provide medical advice, diagnoses, or treatments.Any clinical feedback, treatment planning or suitability discussion remains with the relevant hospital or licensed specialist.
Secure a Remote Case Review with
Dr. Lei Kang
Areas of Expertise
Iodine-131 (I-131) therapy for hyperthyroidism and thyroid cancer.
Strontium-89 (Sr-89) and Radium-223 (Ra-223) treatments for bone metastases.
Diagnosis and comprehensive treatment of various thyroid diseases.
Advanced PET/CT imaging consultations.
Verified Client Satisfaction Metrics
⭐⭐⭐⭐⭐ 5.0/5.0 Overall Rating
* Treatment Pathway Satisfaction:
5.0/5.0
* Communication & Professionalism:
5.0/5.0
* High demand: Chosen online for specialist liaison and case reviews by over:
1,800 clients
(Source: These third-party platform indicators are provided for general reference only. They may change over time and should not be interpreted as a guarantee of diagnosis, treatment suitability, appointment availability, or individual clinical outcome.)
Work Experience
Jan 2022 – Present: Doctoral Supervisor, Department of Nuclear Medicine, Peking University First Hospital.
May 2020 – Present: Master's Supervisor, Department of Nuclear Medicine, Peking University First Hospital.
Aug 2019 – Present: Associate Professor and Associate Chief Physician (Currently Chief Physician), Department of Nuclear Medicine, Peking University First Hospital.
Aug 2015 – Jul 2019: Attending Physician, Department of Nuclear Medicine, Peking University First Hospital.
Aug 2010 – Jul 2015: Resident Physician, Department of Nuclear Medicine, Peking University First Hospital.
Education & Training
Jan 2017 – Jan 2018: Visiting Scholar/Fellow, Department of Radiology and Biomedical Engineering, University of Wisconsin-Madison, USA (Mentor: Prof. Weibo Cai).
Sep 2016 – Dec 2022: Visiting Scholar/Fellow, PET Center, Ronald Reagan Medical Center, University of California, Los Angeles (UCLA), USA (Mentor: Prof. Johannes Czernin).
Awards & Honors
Beijing Outstanding Young Scientist of Natural Science Foundation & Beijing Science and Technology Nova.
Xiao Lun Youth Science and Technology Award (A premier award in Chinese nuclear medicine).
1st Place globally for the CMIIT Young Investigator Award at the 2019 SNM Annual Meeting.
Candidate for the Top Poster Award in Molecular Targeted Probes at the 68th SNMMI Annual Meeting.
2018 SNM Travel Award and 1st Place in the 2018 SNM English Speech Contest (Beijing Division).
Excellent Teacher of Peking University First Hospital (2020-2021).
Peking University Excellent Doctoral Dissertation Award and Peking University First Hospital Research Star of Hope.
Academic & Professional Memberships
Member of the Chinese Medical Association.
Director, Youth Council of the China Photosensitive Society.
Member, Clinical Diagnosis Working Group, Nuclear Medicine Physicians Branch of the Chinese Medical Doctor Association.
Editorial Board Member, 1st Youth Editorial Board of the Chinese Journal of Clinical Oncology.
Deputy Group Leader, Radiopharmacy and Labeled Compounds Professional Group, Nuclear Chemistry and Radiochemistry Branch of the Chinese Nuclear Society.
Expert, Standardized Residency Training Examination Question Bank Construction, National Health Commission.
Member of the PET Group, Translational Medicine Imaging Professional Committee, and Solid Target Nuclide Working Committee, Nuclear Medicine Branch of the Chinese Medical Association.
Member, Nuclear Medicine Professional Group, Tumor Imaging Professional Committee of the Chinese Anti-Cancer Association.
Youth Member, Nuclear Medicine Branch of the Chinese Nuclear Society and Chinese Society of Medical Imaging Technology.
Deputy Group Leader, External Relations and Radiation Protection Group, Nuclear Medicine Branch of the Beijing Medical Association.
Research & Publications
Served as first or corresponding author for nearly 100 SCI papers, including 22 papers with an Impact Factor (IF) > 10 and 45 papers with an IF > 5.
Published in top-tier authoritative journals such as Advanced Science, Nat Commun, Proc Natl Acad Sci, J Clin Invest, J Am Chem Soc, J Nucl Med, and Eur J Nucl Med Mol I.
Led 15 national and municipal research projects, including grants from the National Natural Science Foundation of China, Beijing Science and Technology Nova Talent Plan, and the Ministry of Education.
Holds 1 granted national patent, with 3 additional national patents and 1 US patent pending.
Co-authored two core textbooks on Nuclear Medicine published by the People's Medical Publishing House for five-year and eight-year medical programs.
Selected Peer-Reviewed Publications
Below is a selection of Dr. Kang's highly cited clinical research, demonstrating ongoing leadership in the treatment and diagnostic evaluation of complex conditions:
Gu, T., et al. (2025). B-cell maturation antigen targeted PET/CT imaging in multiple myeloma: a first-in-human study. Journal of Hematology & Oncology. Read on PubMed (PMID: 41239440)
Huang, W., et al. (2024). CD38-specific immunoPET imaging for multiple myeloma diagnosis and therapeutic monitoring: preclinical and first-in-human studies. European Journal of Nuclear Medicine and Molecular Imaging. Read on PubMed (PMID: 39725695)
Liu, Y., et al. (2024). Primary mesenchymal tumors of the prostate: 18F FDG PET/CT findings. EJNMMI Research. Read on PubMed (PMID: 39542970)
*The doctor’s information is sourced from the hospital’s official website or provided directly by the doctor. Due to update cycles, there may be occasional delays in reflecting the most recent changes.
Frequently Asked Questions (FAQs)
How can I request coordination with Dr. Lei Kang before traveling to China?
International patients can contact MedBridgeNZ to request remote specialist-review coordination or pre-travel appointment triage with Dr. Lei Kang’s office where available. With the patient’s authorization, MedBridgeNZ can organize medical records, imaging files and translation support, then assist with secure document transfer and appointment communication. The purpose is to help prepare a clearer pre-travel pathway before considering in-person care in Beijing.
Is Dr. Lei Kang the right nuclear medicine specialist for my condition?
Dr. Lei Kang’s visible clinical focus includes I-131 therapy for hyperthyroidism and thyroid cancer, Sr-89 and Ra-223 therapy for bone metastases, thyroid disease care, and PET/CT imaging consultations. For complex nuclear medicine cases, MedBridgeNZ can help organize your records and questions for preliminary specialist-review coordination or appointment triage where available. Clinical suitability and next steps are determined by the relevant licensed specialist or hospital.
How much might treatment cost in Beijing?
Treatment costs can only be clarified after the relevant hospital or specialist office reviews the case and confirms the possible clinical pathway. After a written specialist response or appointment guidance is available, MedBridgeNZ can help you understand anticipated medical and logistical cost categories so you can plan more clearly. Hospital, specialist, diagnostic, treatment and travel costs are third-party costs unless expressly stated in writing.
Do I need to arrange my own hospital appointments and travel logistics?
No, you do not need to manage the process alone. MedBridgeNZ can assist with appointment request coordination, medical-record preparation, translation coordination, medical invitation or visa-document coordination support, travel planning, accommodation coordination and non-clinical bilingual administrative support in China where available. Appointment availability and clinical decisions remain with the relevant hospital or licensed specialist.
Flexible Ways to Connect with the Specialist
We understand that every client’s situation is unique. Beyond the Remote Written Review, we offer a range of flexible ways to access specialist insights:
-
Remote Video Liaison: For a more personal interaction, we can arrange a live video session, allowing you to discuss your case directly with the specialist with the help of our professional medical translators.
-
On-Site Proxy Liaison: If you cannot travel, our dedicated bilingual team can visit the hospital in person on your behalf. We will present your translated medical records to the specialist, facilitate your inquiries, and provide you with a comprehensive translated report of the doctor’s findings.
-
In-Person Appointment Booking: If you are planning to travel to China for treatment, we manage the complex hospital registration and appointment process, ensuring you have confirmed access to your chosen specialist upon arrival.
How MedBridgeNZ Helps You:
MedBridgeNZ is a medical concierge and logistics coordination provider for international patients seeking specialist-care pathways in China. We help with appointment request coordination, medical-record preparation, translation coordination, medical invitation or visa-document coordination support, travel planning and non-clinical bilingual administrative support. We do not provide medical advice, diagnosis or treatment; clinical decisions remain with the relevant hospital or licensed specialist. Third-party medical, hospital, specialist, diagnostic, treatment, travel or accommodation costs remain separate unless expressly stated in writing.